In a study of Japanese patients, following single doses of 10 mg/kg, 15 mg/kg, and 20 mg/kg, the C max ranged from 362.322 to 735 mcg/mL, and T max was 1.20 to 2.22 hours. 4 AUC was not calculated for the 10 mg/kg dose; for the 15 mg/kg and 20 mg/kg doses, the AUC was 48,000 and 63,400 mcg•h/mL, respectively. 4 The T ½ ranged from 5.33 to 7.29 days. 4 Following single doses of 10 mg/kg, 15 mg/kg, and 20 mg/kg, the C max ranged from 658.391 to 1160 mcg/mL, and T max was 1.74 to 2.21 hours. 4 AUC was not calculated for the 10 mg/kg or 15 mg/kg dose; for the 20 mg/kg dose, the AUC was 123,000 mcg•h/ mL. 4 The T ½ ranged from 4.06 to 8.25 days. 4 The manufacturer reports the steady-state Vd is 7.7 L, and the elimination T ½ is 6 to 24 days. 5 Selected therapeutic regimens of olaratumab appear in Table 1 
ADMINISTRATION
Olaratumab is administered as a short (60 to 90 minute) intravenous infusion.
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%.
A. Cardiovascular: Hypertension 6%. 4 B. Central Nervous System: Headache (grade 1) 5% to 20%. 3 C. Constitutional: Chills (grade 1) 5% to 20%, 3 fatigue (grade 1) 11% to 33%, 3 
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%.
A. Cardiovascular: Dehydration (grade 1 or 2) 5%, 21 (grade 3) 3% 21 ; edema (peripheral) (grade 1 or 2) 11% 21 ; hypotension (grade 1 or 2) 2%, 21 
MECHANISM OF ACTION
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits the PARP1, PARP2, and PARP3 enzymes. PARP1 and PARP2 are involved in repairing single-strand breaks in DNA. Inhibition of PARP1 and PARP2 results in an increase in singlestrand breaks and "trapping" the PARP at the site of the damaged chromatin, resulting in secondary double-strand breaks. [9] [10] [11] [12] [13] [14] PARP3 is involved with regulating DNA damage response, partially through control of PARP1 activity. 15, 16 
PHARMACOKINETICS
Following oral doses ranging from 92 to 600 mg, the T max is 1.5 to 5.5 hours, the C max is 208 to 839 ng/mL, and the T ½ is 2.9 to 9.6 hours. The AUC is 2,312 to 6,852 ng•h/mL, and the Vd was 544 to 831 L. 17 At doses from 1 mg/m 2 to 18 mg/m 2 given as a 30-minute IV infusion, the mean C max ranges from 25 to 863 ng/mL, the mean AUC is 21 to 2882 ng•h/mL, and the mean Vd is 111 to 584 L. The mean T ½ is 1.2 to 23.2 hours. 18 Following 240 to 840 mg given orally twice a day, the mean C max is 1,940 ng/mL, and the mean T max is 1.9 hours. The mean bioavailability of oral rucaparib is 36% (range, 30%-40%); the mean AUC is 16,900 ng•h/mL. Following a high-fat meal, the C max increases 20%, the AUC increases 38%, and the T ½ is delayed by 2.5 hours. Rucaparib in metabolized in the liver by CYP2D6 (primary), CYP1A2, and CYP3A4. 19 The mean terminal T ½ is 17 hours following IV doses of 12 to 40 mg; the Vd is 113 to 262 L. Following a single oral dose of 600 mg, the terminal T ½ is 17 to 19 hours. 19 Selected therapeutic regimens of rucaparib appear in Table 2 .
PREPARATION
Rucaparib is available as 200 mg and 300 mg tablets. (grade 1 or 2) 2%, 21 Note: bid = twice daily; IV = intravenous; PO = oral. a Conforms to dosing information listed in the manufacturer's labeling. b Although IV rucaparib has been studied, as parenteral formulation is not commercially available.
E. Endocrine/Metabolic: Hyperglycemia

